{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:54:13Z","timestamp":1790830453946,"version":"4.1.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.coviro.2016.06.001","type":"journal-article","created":{"date-parts":[[2016,6,19]],"date-time":"2016-06-19T07:45:35Z","timestamp":1466322335000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Viral vectors as vaccine carriers"],"prefix":"10.1016","volume":"21","author":[{"given":"Hildegund CJ","family":"Ertl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2016.06.001_bib0580","first-page":"201","article-title":"Use of vaccinia virus as an infectious molecular cloning and expression vector","volume":"3","author":"Moss","year":"1983","journal-title":"Gene Amplif Anal"},{"key":"10.1016\/j.coviro.2016.06.001_bib0585","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1586\/14760584.3.4.S89","article-title":"MVA as a vector for vaccines against HIV-1","volume":"3","author":"Im","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2016.06.001_bib0590","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/j.vaccine.2013.05.091","article-title":"Utilizing poxviral vectored vaccines for antibody induction-progress and prospects","volume":"31","author":"Draper","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.06.001_bib0595","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/14760584.2016.1114418","article-title":"Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses","volume":"15","author":"Russell","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2016.06.001_bib0600","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/JVI.02308-14","article-title":"Rhabdovirus-based vaccine platforms against henipaviruses","volume":"89","author":"Kurup","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0605","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1128\/JVI.02598-15","article-title":"Vaccination with vesicular stomatitis virus-vectored chimeric hemagglutinins protects mice against divergent influenza virus challenge strains","volume":"90","author":"Ryder","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0610","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.nano.2015.11.007","article-title":"Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin","volume":"12","author":"Lee","year":"2016","journal-title":"Nanomedicine Nanotechnol Biol Med"},{"key":"10.1016\/j.coviro.2016.06.001_sbref0615","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vaccine.2014.10.004","article-title":"Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"33","author":"Monath","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.06.001_bib0620","doi-asserted-by":"crossref","first-page":"e0150213","DOI":"10.1371\/journal.pone.0150213","article-title":"Recombinant measles AIK-C vaccine strain expressing the prM-E antigen of Japanese Encephalitis Virus","volume":"11","author":"Higuchi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2016.06.001_bib0625","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-1-4939-3389-1_24","article-title":"Generation of lymphocytic choriomeningitis virus based vaccine vectors","volume":"1404","author":"Ring","year":"2016","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"10.1016\/j.coviro.2016.06.001_bib0630","first-page":"363","article-title":"Adenovirus-based expression vectors and recombinant vaccines","volume":"20","author":"Graham","year":"1992","journal-title":"Biotechnol Read Mass"},{"key":"10.1016\/j.coviro.2016.06.001_sbref0635","series-title":"Rabies vaccines based on E1 deleted recombinant adenovirus In Vaccine 96","first-page":"189","author":"Xiang","year":"1996"},{"key":"10.1016\/j.coviro.2016.06.001_bib0640","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.vaccine.2006.11.025","article-title":"Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41","volume":"25","author":"Lemiale","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.06.001_bib0645","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrmicro3360","article-title":"Novel vaccine vectors for HIV-1","volume":"12","author":"Barouch","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coviro.2016.06.001_sbref0650","doi-asserted-by":"crossref","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2016.06.001_bib0655","doi-asserted-by":"crossref","first-page":"16030","DOI":"10.1038\/mtm.2016.30","article-title":"Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens","volume":"3","author":"Afkhami","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.coviro.2016.06.001_bib0660","doi-asserted-by":"crossref","first-page":"e0142349","DOI":"10.1371\/journal.pone.0142349","article-title":"A novel adeno-associated virus-based genetic vaccine encoding the Hepatitis C Virus NS3\/4 protein exhibits immunogenic properties in mice superior to those of an NS3-protein-based vaccine","volume":"10","author":"Zhu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2016.06.001_bib0665","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis699","article-title":"Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines","volume":"207","author":"Ploquin","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.06.001_bib0670","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.micinf.2012.05.002","article-title":"Novel AAV-based genetic vaccines encoding truncated dengue virus envelope proteins elicit humoral immune responses in mice","volume":"14","author":"Li","year":"2012","journal-title":"Microbes Infect Inst Pasteur"},{"key":"10.1016\/j.coviro.2016.06.001_bib0675","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/hum.2011.202","article-title":"Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques","volume":"23","author":"Nieto","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.001_bib0680","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.vaccine.2006.09.072","article-title":"AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection","volume":"25","author":"Logan","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.06.001_bib0685","doi-asserted-by":"crossref","first-page":"1237874","DOI":"10.1126\/science.1237874","article-title":"Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms","volume":"340","author":"Hansen","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.06.001_bib0690","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0952-7915(03)00070-0","article-title":"Toll-like receptors and innate antiviral responses","volume":"15","author":"Vaidya","year":"2003","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0695","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coviro.2015.02.007","article-title":"Inflammasome control of viral infection","volume":"12","author":"Lupfer","year":"2015","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0700","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.imbio.2013.07.007","article-title":"The interferon response to intracellular DNA: why so many receptors?","volume":"218","author":"Unterholzner","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.coviro.2016.06.001_sbref0705","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/embj.201488027","article-title":"Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming","volume":"33","author":"Dalod","year":"2014","journal-title":"EMBO J"},{"key":"10.1016\/j.coviro.2016.06.001_bib0710","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.coi.2007.05.006","article-title":"Innate signaling and regulation of Dendritic cell immunity","volume":"19","author":"van Vliet","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0715","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.coi.2007.04.009","article-title":"Affinity of antigen encounter and other early B-cell signals determine B-cell fate","volume":"19","author":"Benson","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0720","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jb\/mvm106","article-title":"Architecture and dynamics of the transcription factor network that regulates B-to-plasma cell differentiation","volume":"141","author":"Igarashi","year":"2007","journal-title":"J Biochem (Tokyo)"},{"key":"10.1016\/j.coviro.2016.06.001_sbref0725","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12396","article-title":"Regulation of germinal center B-cell differentiation","volume":"270","author":"Zhang","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coviro.2016.06.001_bib0730","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/sji.12336","article-title":"Regulation of B cell to plasma cell transition within the follicular B cell response","volume":"82","author":"Nera","year":"2015","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0735","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02918494","article-title":"Lifespan of lymphocytes","volume":"14","author":"Tough","year":"1995","journal-title":"Immunol Res"},{"key":"10.1016\/j.coviro.2016.06.001_bib0740","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-065X.2010.00924.x","article-title":"The immortality of humoral immunity","volume":"236","author":"Elgueta","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coviro.2016.06.001_bib0745","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF02935617","article-title":"Endogenous antigen presentation by MHC class II molecules","volume":"13","author":"Sant","year":"1994","journal-title":"Immunol Res"},{"key":"10.1016\/j.coviro.2016.06.001_bib0750","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fimmu.2015.00363","article-title":"Cross-presentation of cell-associated antigens by MHC Class I in dendritic cell subsets","volume":"6","author":"Guti\u00e9rrez-Mart\u00ednez","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0755","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/eji.201142205","article-title":"From crucial to negligible: functional CD8+ T-cell responses and their dependence on CD4+ T-cell help","volume":"42","author":"Wiesel","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0760","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nri1485","article-title":"Regulatory T cells: friend or foe in immunity to infection?","volume":"4","author":"Mills","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0765","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nri778","article-title":"Effector and memory T-cell differentiation: implications for vaccine development","volume":"2","author":"Kaech","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0770","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fimmu.2012.00358","article-title":"Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination","volume":"3","author":"Vasconcelos","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0775","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0952-7915(00)00211-9","article-title":"Generation and maintenance of memory T cells","volume":"13","author":"Sprent","year":"2001","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0780","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/icb.2010.155","article-title":"Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines","volume":"89","author":"Ahmed","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0785","doi-asserted-by":"crossref","first-page":"e1694","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.coviro.2016.06.001_bib0790","first-page":"453","article-title":"PD-1\/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection","volume":"17","author":"Watanabe","year":"2010","journal-title":"J Viral Hepatol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0795","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.humimm.2004.02.004","article-title":"Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry","volume":"65","author":"Maecker","year":"2004","journal-title":"Hum Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0800","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/mt.2011.81","article-title":"Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates","volume":"19","author":"Li","year":"2011","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.001_bib0805","first-page":"325","article-title":"T-Cell responses to EBV","volume":"391","author":"Hislop","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0810","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1086\/519742","article-title":"Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells","volume":"196","author":"Tarun","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.06.001_bib0815","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","article-title":"Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine","volume":"473","author":"Hansen","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.06.001_bib0820","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2362.1994.tb01055.x","article-title":"T cell recognition of hepatitis B and C viral antigens","volume":"24","author":"Jung","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.coviro.2016.06.001_bib0825","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/eji.1830061004","article-title":"Role of early viral surface antigens in cellular immune response to vaccinia virus","volume":"6","author":"Koszinowski","year":"1976","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0830","first-page":"199","article-title":"The origin of the genetic variability of influenza viruses","volume":"146","author":"Salazar","year":"2010","journal-title":"Gac. M\u00e9dica M\u00e9xico"},{"issue":"Suppl 2","key":"10.1016\/j.coviro.2016.06.001_bib0835","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/00002030-199101001-00005","article-title":"Sequence variability in human immunodeficiency viruses: pattern and process in viral evolution","volume":"5","author":"Brown","year":"1991","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.coviro.2016.06.001_sbref0840","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.coi.2010.04.002","article-title":"Designing CD8+ T cell vaccines: it's not rocket science (yet)","volume":"22","author":"Yewdell","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0845","first-page":"4809","article-title":"Cutting edge: recombinant adenoviruses induce CD8T cell responses to an inserted protein whose expression is limited to nonimmune cells","volume":"166","author":"Prasad","year":"2001","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.coviro.2016.06.001_bib0850","doi-asserted-by":"crossref","first-page":"e6376","DOI":"10.1371\/journal.pone.0006376","article-title":"Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity","volume":"4","author":"Martino","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2016.06.001_sbref0855","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3201\/eid1210.060078","article-title":"Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa","volume":"12","author":"Xiang","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2016.06.001_bib0860","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1086\/314498","article-title":"Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey","volume":"178","author":"Ludwig","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.06.001_bib0865","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/JCM.01249-06","article-title":"Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa","volume":"44","author":"Thorner","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0870","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.001_sbref0875","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.06.001_bib0880","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/sj.gt.3301611","article-title":"Complement activation by recombinant adenoviruses","volume":"8","author":"Cichon","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.001_sbref0885","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.coviro.2016.06.001_bib0890","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.gt.3302675","article-title":"Chimpanzee-origin adenovirus vectors as vaccine carriers","volume":"13","author":"Tatsis","year":"2006","journal-title":"Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.001_bib0895","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1586\/erv.13.15","article-title":"Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials","volume":"12","author":"Capone","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2016.06.001_bib0900","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.virol.2013.05.041","article-title":"Adenoviruses isolated from wild gorillas are closely related to human species C viruses","volume":"444","author":"Duncan","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2016.06.001_bib0905","doi-asserted-by":"crossref","first-page":"12738","DOI":"10.1128\/JVI.01441-09","article-title":"A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque","volume":"83","author":"Lin","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0910","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.vaccine.2009.10.091","article-title":"Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive","volume":"28","author":"Hutnick","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.06.001_bib0915","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2016.06.001_bib0920","first-page":"1416","article-title":"A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag","volume":"170","author":"Fitzgerald","year":"2003","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.coviro.2016.06.001_bib0925","doi-asserted-by":"crossref","first-page":"7909","DOI":"10.1128\/JVI.72.10.7909-7915.1998","article-title":"The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F","volume":"72","author":"Roelvink","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0930","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1128\/JVI.68.10.6811-6814.1994","article-title":"Multiple adenovirus serotypes use alpha v integrins for infection","volume":"68","author":"Mathias","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0935","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1128\/JVI.78.9.4454-4462.2004","article-title":"The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3","volume":"78","author":"Sirena","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0940","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2016.06.001_bib0945","doi-asserted-by":"crossref","first-page":"e101591","DOI":"10.1371\/journal.pone.0101591","article-title":"Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial","volume":"9","author":"Hayton","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2016.06.001_bib0950","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.yjmcc.2011.02.011","article-title":"The coxsackie-adenovirus receptor induces an inflammatory cardiomyopathy independent of viral infection","volume":"50","author":"Yuen","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0955","doi-asserted-by":"crossref","first-page":"113","DOI":"10.18632\/oncotarget.231","article-title":"The challenge for gene therapy: innate immune response to adenoviruses","volume":"2","author":"Thaci","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.coviro.2016.06.001_bib0960","first-page":"2134","article-title":"Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo","volume":"181","author":"Appledorn","year":"2008","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.coviro.2016.06.001_bib0965","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1089\/hum.2007.016","article-title":"Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors","volume":"18","author":"Yamaguchi","year":"2007","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.001_sbref0970","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/JVI.77.11.6305-6313.2003","article-title":"Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene","volume":"77","author":"Casimiro","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.001_bib0975","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1073\/pnas.1407466112","article-title":"Activated CD4+CCR5+T cells in the rectum predict increased SIV acquisition in SIVGag\/Tat-vaccinated rhesus macaques","volume":"112","author":"Carnathan","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.06.001_bib0980","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.virol.2013.12.029","article-title":"Protection of non-human primates against rabies with an adenovirus recombinant vaccine","volume":"450","author":"Xiang","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2016.06.001_bib0985","doi-asserted-by":"crossref","first-page":"e6559","DOI":"10.1371\/journal.pone.0006559","article-title":"Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies","volume":"4","author":"Jiang","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2016.06.001_bib0990","doi-asserted-by":"crossref","first-page":"e107903","DOI":"10.1371\/journal.pone.0107903","article-title":"Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure","volume":"9","author":"Biswas","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2016.06.001_bib0995","doi-asserted-by":"crossref","first-page":"7881","DOI":"10.1016\/j.vaccine.2010.09.079","article-title":"Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans","volume":"28","author":"Bett","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.06.001_bib1000","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1016\/j.vaccine.2008.09.007","article-title":"Comparison of multiple vaccine vectors in a single heterologous prime-boost trial","volume":"26","author":"Barefoot","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.06.001_sbref1005","doi-asserted-by":"crossref","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2016.06.001_bib1010","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.1128\/JVI.00450-10","article-title":"Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae","volume":"84","author":"Chen","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.001_bib1015","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2007-02-062117","article-title":"Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines","volume":"110","author":"Tatsis","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2016.06.001_bib1020","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.1128\/JVI.78.14.7392-7399.2004","article-title":"Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes","volume":"78","author":"Reyes-Sandoval","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.001_bib1025","article-title":"Safety and immunogenicity of the MRKAd5 gag HIV Type 1 vaccine in a worldwide Phase 1 Study of Healthy Adults","author":"Nicholson","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.coviro.2016.06.001_bib1030","doi-asserted-by":"crossref","first-page":"e21225","DOI":"10.1371\/journal.pone.0021225","article-title":"A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)","volume":"6","author":"Churchyard","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2016.06.001_bib1035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.06.001_bib1040","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1016\/j.vaccine.2014.09.001","article-title":"The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses","volume":"32","author":"Kagina","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.06.001_bib1045","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals","volume":"211","author":"Hodgson","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2016.06.001_bib1050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2016.06.001_bib1055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1566523054065057","article-title":"New recombinant serotypes of AAV vectors","volume":"5","author":"Gao","year":"2005","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.001_bib1060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0166-0934(97)00198-5","article-title":"Discrimination between different types of human adeno-associated viruses in clinical samples by PCR","volume":"71","author":"Tobiasch","year":"1998","journal-title":"J Virol Methods"},{"key":"10.1016\/j.coviro.2016.06.001_bib1065","doi-asserted-by":"crossref","first-page":"14781","DOI":"10.1128\/JVI.79.23.14781-14792.2005","article-title":"Molecular characterization of adeno-associated viruses infecting children","volume":"79","author":"Chen","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.001_bib1070","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/mt.2008.100","article-title":"Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles","volume":"16","author":"Li","year":"2008","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.001_bib1075","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1128\/JVI.00526-06","article-title":"High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes","volume":"80","author":"Gao","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.001_bib1080","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2016.06.001_bib1085","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors","volume":"55","author":"H\u00f6sel","year":"2012","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.coviro.2016.06.001_bib1090","doi-asserted-by":"crossref","first-page":"e53845","DOI":"10.1371\/journal.pone.0053845","article-title":"Activation of the cellular unfolded protein response by recombinant adeno-associated virus vectors","volume":"8","author":"Balakrishnan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2016.06.001_bib1095","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nature13818","article-title":"Mitochondrial UPR-regulated innate immunity provides resistance to pathogen infection","volume":"516","author":"Pellegrino","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.06.001_bib1100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/mt.2010.250","article-title":"The complex and evolving story of T cell activation to AAV vector-encoded transgene products","volume":"19","author":"Mays","year":"2011","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.001_bib1105","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1089\/104303402760128513","article-title":"Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy","volume":"13","author":"Herzog","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.001_bib1110","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/mt.2011.280","article-title":"Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome","volume":"20","author":"Wu","year":"2012","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.001_bib1115","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.coviro.2016.06.001_bib1120","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/hum.2015.29014.kib","article-title":"Adeno-associated virus Type 2 and hepatocellular carcinoma?","volume":"26","author":"Berns","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.001_sbref1125","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1089\/aid.2007.0292","article-title":"A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine","volume":"24","author":"Mehendale","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.coviro.2016.06.001_sbref1130","first-page":"3958","article-title":"Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice","volume":"117","author":"Lin","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2016.06.001_bib1135","doi-asserted-by":"crossref","first-page":"11840","DOI":"10.1128\/JVI.01253-07","article-title":"Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice","volume":"81","author":"Lin","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.001_bib1140","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1089\/aid.2009.0242","article-title":"A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus","volume":"26","author":"Vardas","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.coviro.2016.06.001_bib1145","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2016.06.001_bib1150","doi-asserted-by":"crossref","first-page":"e66134","DOI":"10.1371\/journal.pone.0066134","article-title":"IFN-\u03b1 as an adjuvant for adenovirus-vectored FMDV subunit vaccine through improving the generation of T follicular helper cells","volume":"8","author":"Su","year":"2013","journal-title":"PLoS One"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716300633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716300633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T11:11:07Z","timestamp":1600773067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625716300633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":115,"alternative-id":["S1879625716300633"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2016.06.001","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral vectors as vaccine carriers","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2016.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}